Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 3Terminated 2Unknown 1Not yet recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Dermatologic 1

Conditions

Melanoma 1

Interventions

Nivolumab 6pembrolizumab 3Ipilimumab 3relatlimab 2cemiplimab 2Specimen Handling 2Melphalan 2Magnetic Resonance Spectroscopy 2Interleukin-2 2vedolizumab 1trametinib 1toripalimab 1sulforaphane 1gadopiclenol 1famitinib 1anlotinib 1X-Rays 1Watchful Waiting 1Toll-Like Receptor 1 1Therapeutics 1Temozolomide 1Technetium 1Standard of Care 1Sentinel Lymph Node Biopsy 1SHR-1701 1Rehabilitation 1Photopheresis 1Pemetrexed 1Paclitaxel 1Observation 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Not yet recruiting × Melanoma × Toll-Like Receptor 1 × Clear all
NCT07406724 2026-02-12

HS-IT101 Injection Versus Chemotherapy in the Treatment of Advanced Melanoma

Qingdao Sino-Cell Biomedicine Co., Ltd.

Phase 2 Not yet recruiting
90 enrolled
Dermatologic

Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡